Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -42.07 Million USD | 63.55% |
| 2021 | -115.43 Million USD | -26.31% |
| 2020 | -91.38 Million USD | 1.62% |
| 2019 | -92.89 Million USD | -62.17% |
| 2018 | -57.28 Million USD | -92.96% |
| 2017 | -29.68 Million USD | 22.56% |
| 2016 | -38.33 Million USD | -16.8% |
| 2015 | -32.81 Million USD | -51.09% |
| 2014 | -21.72 Million USD | -75.48% |
| 2013 | -12.37 Million USD | -55.21% |
| 2012 | -7.97 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 Q2 | -11.37 Million USD | 17.72% |
| 2022 Q3 | -9.52 Million USD | 16.26% |
| 2022 Q4 | -7.34 Million USD | 22.88% |
| 2022 Q1 | -13.82 Million USD | 80.02% |
| 2022 FY | -42.07 Million USD | 63.55% |
| 2021 Q1 | -20.76 Million USD | 8.37% |
| 2021 Q4 | -69.2 Million USD | -520.71% |
| 2021 Q2 | -14.3 Million USD | 31.11% |
| 2021 Q3 | -11.15 Million USD | 22.07% |
| 2021 FY | -115.43 Million USD | -26.31% |
| 2020 FY | -91.38 Million USD | 1.62% |
| 2020 Q4 | -22.66 Million USD | 1.04% |
| 2020 Q2 | -20.75 Million USD | 17.23% |
| 2020 Q3 | -22.9 Million USD | -10.36% |
| 2020 Q1 | -25.07 Million USD | -11.66% |
| 2019 Q4 | -22.45 Million USD | -6.28% |
| 2019 Q2 | -24.91 Million USD | -2.09% |
| 2019 FY | -92.89 Million USD | -62.17% |
| 2019 Q1 | -24.4 Million USD | -20.66% |
| 2019 Q3 | -21.12 Million USD | 15.19% |
| 2018 Q4 | -20.22 Million USD | -3.68% |
| 2018 Q2 | -3.73 Million USD | 72.94% |
| 2018 Q1 | -13.81 Million USD | -19.67% |
| 2018 FY | -57.28 Million USD | -92.96% |
| 2018 Q3 | -19.5 Million USD | -421.86% |
| 2017 Q4 | -11.54 Million USD | -73.49% |
| 2017 Q2 | -5.73 Million USD | 0.36% |
| 2017 Q1 | -5.75 Million USD | 40.07% |
| 2017 FY | -29.68 Million USD | 22.56% |
| 2017 Q3 | -6.65 Million USD | -16.01% |
| 2016 Q1 | -9.65 Million USD | -18.81% |
| 2016 FY | -38.33 Million USD | -16.8% |
| 2016 Q4 | -9.6 Million USD | -11.26% |
| 2016 Q3 | -8.63 Million USD | 17.33% |
| 2016 Q2 | -10.44 Million USD | -8.12% |
| 2015 FY | -32.81 Million USD | -51.09% |
| 2015 Q4 | -8.12 Million USD | 9.18% |
| 2015 Q3 | -8.95 Million USD | -13.67% |
| 2015 Q2 | -7.87 Million USD | -0.09% |
| 2015 Q1 | -7.86 Million USD | -15.05% |
| 2014 Q2 | -5.49 Million USD | -32.34% |
| 2014 FY | -21.72 Million USD | -75.48% |
| 2014 Q4 | -6.83 Million USD | -30.47% |
| 2014 Q3 | -5.24 Million USD | 4.57% |
| 2014 Q1 | -4.15 Million USD | -1.52% |
| 2013 Q4 | -4.08 Million USD | -23.21% |
| 2013 Q3 | -3.31 Million USD | 0.0% |
| 2013 FY | -12.37 Million USD | -55.21% |
| 2012 FY | -7.97 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -8440.447% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -342.047% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -40.279% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 37.337% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -165.568% |
| Better Therapeutics, Inc. | -38.26 Million USD | -9.963% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -251.495% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -24.317% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -22.241% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 61.21% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1988.763% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -23.74% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 10.387% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2976.966% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -111.01% |
| Molecular Templates, Inc. | -10.46 Million USD | -302.006% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -199.44% |
| NexImmune, Inc. | -29.19 Million USD | -44.126% |
| Orgenesis Inc. | -53.63 Million USD | 21.556% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 17.975% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -53829.272% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -160.596% |
| Scopus BioPharma Inc. | -11.71 Million USD | -259.15% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 91.657% |
| Statera Biopharma, Inc. | -98.34 Million USD | 57.217% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -509.945% |
| Trevena, Inc. | -35.28 Million USD | -19.23% |
| Vaxxinity, Inc. | -58.28 Million USD | 27.813% |
| Vaccinex, Inc. | -22.88 Million USD | -83.85% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3918.614% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 17.002% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -479.291% |